Surmodics (NASDAQ:SRDX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Surmodics (NASDAQ:SRDX) in a report released on Friday. The brokerage issued a hold rating on the stock.

Other equities research analysts also recently issued research reports about the company. Lake Street Capital reissued a hold rating and set a $43.00 price objective on shares of Surmodics in a report on Wednesday, May 29th. Barrington Research reaffirmed a market perform rating on shares of Surmodics in a research report on Thursday, May 30th. Sidoti reaffirmed a neutral rating and set a $43.00 price target on shares of Surmodics in a research note on Wednesday, May 29th. Finally, Needham & Company LLC reiterated a hold rating on shares of Surmodics in a report on Monday, August 5th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Surmodics has a consensus rating of Hold and an average price target of $50.00.

Surmodics Stock Performance

Shares of SRDX stock opened at $39.34 on Friday. Surmodics has a one year low of $25.17 and a one year high of $42.44. The stock has a market cap of $560.99 million, a P/E ratio of 41.41 and a beta of 1.20. The company has a fifty day moving average price of $40.29 and a two-hundred day moving average price of $36.34. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.22.

Surmodics (NASDAQ:SRDX) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.04. The business had revenue of $30.34 million during the quarter, compared to the consensus estimate of $30.32 million. Surmodics had a positive return on equity of 3.88% and a negative net margin of 1.16%. As a group, equities analysts predict that Surmodics will post -0.47 EPS for the current year.

Institutional Trading of Surmodics

Several hedge funds and other institutional investors have recently bought and sold shares of SRDX. US Bancorp DE increased its stake in shares of Surmodics by 61.9% in the 4th quarter. US Bancorp DE now owns 16,190 shares of the company’s stock worth $589,000 after acquiring an additional 6,193 shares in the last quarter. Quadrature Capital Ltd purchased a new position in shares of Surmodics in the fourth quarter worth approximately $504,000. Mesirow Financial Investment Management Inc. bought a new stake in Surmodics during the first quarter valued at approximately $223,000. BNP Paribas Financial Markets increased its holdings in Surmodics by 7.5% during the first quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock valued at $202,000 after buying an additional 481 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in Surmodics by 14.7% in the first quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock worth $151,000 after acquiring an additional 660 shares during the period. Institutional investors own 96.63% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).